US 12,447,170 B2
Use of maribavir in treatment regimens
Heng Song, Cambridge, MA (US); Kefeng Sun, Needham, MA (US); Matthew Crouthamel, Chelmsford, MA (US); Grace Chen, Libertyville, IL (US); Andy Z. X. Zhu, Winchester, MA (US); Ingrid Nicolle Michon, Voorschoten (NL); Howard James Burt, Sheffield (GB); Zoe Elizabeth Barter, Nottingham (GB); and Sibylle Neuhoff, Sheffield (GB)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Dec. 20, 2024, as Appl. No. 18/990,486.
Application 18/990,486 is a continuation of application No. 18/646,035, filed on Apr. 25, 2024, granted, now 12,213,989.
Application 18/646,035 is a continuation of application No. 18/400,304, filed on Dec. 29, 2023, abandoned.
Application 18/400,304 is a continuation of application No. PCT/US2022/050341, filed on Nov. 18, 2022.
Claims priority of provisional application 63/281,206, filed on Nov. 19, 2021.
Prior Publication US 2025/0144124 A1, May 8, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7056 (2006.01); A61K 31/4166 (2006.01); A61K 31/513 (2006.01); A61K 31/55 (2006.01)
CPC A61K 31/7056 (2013.01) [A61K 31/4166 (2013.01); A61K 31/513 (2013.01); A61K 31/55 (2013.01)] 25 Claims
 
1. A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom, the method comprising administering maribavir in an amount of 1200 mg orally twice daily to the patient,
wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant and an immunosuppressant, and wherein the amount of maribavir is selected to counteract the effect of the anticonvulsant from an efficacy perspective;
wherein the method further comprises monitoring immunosuppressant drug levels in blood throughout treatment with maribavir,
wherein the patient is an adult, or a child of 12 years of age or older and weighing at least 35 kg, and wherein the patient is refractory to treatment with one or more of ganciclovir, valganciclovir, cidofovir, or foscarnet.